{"entity":{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","aka":[],"tldr":"The two trials that made everolimus a standard pill for pancreatic, lung and gut neuroendocrine tumours.","summary":"RADIANT-3 and RADIANT-4, led by trial NCT00510068 and sponsored by Novartis, are the two trials, reported from 2011, that made everolimus a standard tablet for pancreatic, lung and gastrointestinal neuroendocrine tumours. RADIANT-3 randomised 410 patients with progressive pancreatic neuroendocrine tumours and RADIANT-4 302 patients with lung or gastrointestinal tumours to everolimus or placebo, and both met their primary progression-free survival endpoints with large effects, while overall survival was not significantly improved because of crossover. OnCo links them to neuroendocrine tumours, everolimus and James C. Yao. Whether everolimus should come before or after radioligand therapy, which COMPETE has now tested directly, is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT00510068","url":"https://clinicaltrials.gov/study/NCT00510068"}],"tags":[],"related":[],"cancers":["neuroendocrine","pancreatic-net","small-intestinal-net","lung-net"],"sections":[],"technologies":["kinase-inhibitors","pi3k-akt-mtor-inhibitors"],"targets":[],"drugs":["everolimus"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["james-yao"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00510068","phase":"3","setting":"Progressive pancreatic NETs (RADIANT-3, n=410) and lung/GI NETs (RADIANT-4, n=302): everolimus vs placebo","sponsor":"Novartis","result":"PFS HR 0.35 (pNET) and 0.48 (lung/GI).","started":"2007-07","yearReported":2011,"enrolled":712,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (RADIANT-3)","primary":true,"unit":"months","arms":[{"name":"Everolimus","n":207,"value":11},{"name":"Placebo","n":203,"value":4.6}],"hr":0.35,"ci":[0.27,0.45],"source":"https://doi.org/10.1056/NEJMoa1009290"},{"endpoint":"Progression-free survival (RADIANT-4)","primary":true,"unit":"months","arms":[{"name":"Everolimus","n":205,"value":11},{"name":"Placebo","n":97,"value":3.9}],"hr":0.48,"ci":[0.35,0.67],"source":"https://doi.org/10.1016/S0140-6736(15)00817-X"}]},"route":"/trials/radiant-3-4/","neighbours":{"cancer":[{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"person":[{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/"}]}}